Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin's lymphoma, in healthy Chinese volunteers

• Main Authors: Chun-Yang Zhao (Author), Li-Jun Zhang (Author), Chan Sun (Author), Cheng-Yin Yu (Author), Jian Wang (Author), Yang Sai (Author), Wei-Guo Su (Author), Qian Chen (Author), Wei Wang (Author), Jing-Ying Jia (Author), Gang-Yi Liu (Author), Yan-Mei Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionAmdizalisib (HMPL-689) is an ATP-competitive PI3Kδ inhibitor currently under investigation for treating Hodgkin's lymphoma. This study aimed to evaluate the metabolism, excretion, pharmacokinetics, and safety profile of amdizalisib in healthy human subjects to support its clinical a...